ProCE Banner Activity

CE

Advances in R/R Multiple Myeloma: Practical Guidance for Newly Approved and Emerging Therapies

Multimedia
In this on-demand webcast from a live symposium, pharmacy and oncology experts Kathryn Maples, PharmD, BCOP, and Sagar Lonial, MD, discuss best practices in using newer agents to improve outcomes in patients with relapsed/refractory multiple myeloma.

Pharmacists: 1.00 contact hour (0.1 CEUs)

Released: May 28, 2021

Expiration: May 27, 2022

No longer available for credit.

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Kathryn Maples

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist, Multiple Myeloma
Department of Pharmacy
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

Bristol Myers Squibb

Karyopharm Therapeutics

Target Audience

This educational program is intended for oncology pharmacists and other healthcare providers who care for patients with relapsed/refractory multiple myeloma.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the efficacy and safety evidence of novel combination therapeutic regimens for R/R MM
  • Delineate the dose, schedule of administration, and dose modifications for newer classes of agents indicated or emerging for R/R MM
  • Counsel patients with heavily pretreated MM about potential risks and drug–drug interactions when starting new therapies based on comorbidities, comedications, and previous therapies
  • Refer to current resources for management of toxicities with newer agents and combination regimens in patients with heavily pretreated R/R MM
  • Evaluate ongoing major clinical trials investigating novel therapeutic approaches in R/R MM

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb, Celgene, Janssen, and Takeda; has received consulting fees from AbbVie, Bluebird, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Takeda; and owns stock in TG Therapeutics.

Kathryn Maples, PharmD, BCOP

Clinical Pharmacy Specialist, Multiple Myeloma
Department of Pharmacy
Emory Healthcare
Winship Cancer Institute
Atlanta, Georgia

Kathryn Maples, PharmD, BCOP, has disclosed that she has received consulting fees from GlaxoSmithKline, Karyopharm, and Sanofi.

Staff Disclosure

Staff

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD has no relevant conflicts of interest to report.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-118-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 28, 2021, through May 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate oncology pharmacists and other healthcare professionals about the recent improvements in the care of R/R MM and applying those improvements to their patients.